Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 21, 2025 08:00 ET | Source: Simcha Therapeutics

Simcha Therapeutics Presents Preclinical Data Demonstrating Potential for Decoy-Resistant IL-18 to Enhance Efficacy of Bi-specific T-cell Engagers

SOUTH SAN FRANCISCO, Calif., and NEW HAVEN, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Simcha Therapeutics (“Simcha”), a clinical-stage immunobiology company pioneering first-in-class cytokine...
October 21, 2025 06:12 ET | Source: Janssen Cilag International NV

RYBREVANT®▼ par voie sous-cutanée (amivantamab) offre un taux de réponse global prometteur de 45 pour cent associé à une durée de réponse médiane de 7,2 mois dans le cancer de la tête et du cou récurrent ou métastatique

Les réponses étaient rapides et durables, et une réduction tumorale a été observée chez 82 pour cent des patients1 Les nouveaux résultats issus de cette étude expérimentale s’appuient sur la solidité...
October 21, 2025 03:27 ET | Source: Nxera Pharma

Nxera’s Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO

HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of cancers in combination with other immunotherapiesHTL0039732, was found to be...
October 20, 2025 10:30 ET | Source: https://immatics.com/

Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium

One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy in 16 patients with metastatic uveal melanoma in the ongoing Phase 1b trial continues to show strong clinical benefit...
October 20, 2025 08:01 ET | Source: Immutep Limited

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

Novel combination including eftilagimod alfa (efti) in neoadjuvant setting drives 51.5% tumour hyalinization/fibrosis in patients with soft tissue sarcoma (p<0.001) High level of tumour...
October 20, 2025 08:00 ET | Source: Immutep Limited

Two Posters at ESMO Congress 2025 Highlight Immutep’s Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer

Novel combination of efti with KEYTRUDA® and chemotherapy generates strong response rates across all PD-L1 expression levels in first line non-small cell lung cancer (1L NSCLC) including 61.7% ORR in...
October 20, 2025 08:00 ET | Source: BioAtla, Inc.

BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025

Adverse events (AEs) generally transient and readily manageable; only 2 cases of cytokine release syndrome (CRS)Prolonged tumor control with increasing doses of BA3182; confirmed partial response...
October 20, 2025 07:30 ET | Source: BriaCell Therapeutics Corp.

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Biomarkers identified in BriaCell’s Phase 2 study are showing similar and encouraging trends in the ongoing pivotal Phase 3 study of Bria-IMT™ in metastatic breast cancer (MBC)No new safety or...
October 20, 2025 07:10 ET | Source: OGRD Alliance L.L.C-FZ

OGRD Alliance Expands OncoVix and PLPC-DB Initiatives from the Emirates to Asia and MENA Regions

DUBAI, United Arab Emirates, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Following recent licensing frameworks and the international exposure of the PLPC Platform, the American-born biotechnology system —...
October 20, 2025 04:15 ET | Source: Arvinas Inc.

Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

– Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of overall health, daily functioning, and symptoms, including...